Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
about
The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research.Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset.Long-term functional outcomes after treatment for localized prostate cancer.The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology GroupStudy protocol of an equivalence randomized controlled trial to evaluate the effectiveness of three different approaches to collecting Patient Reported Outcome Measures (PROMs) data using the Prostate Cancer Outcomes Registry-Victoria (PCOR-VIC)PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trialComparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments.Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy.Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomesA pilot randomised controlled trial of personalised care after treatment for prostate cancer (TOPCAT-P): nurse-led holistic-needs assessment and individualised psychoeducational intervention: study protocolThe Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trialA comparison of extraperitoneal and intraperitoneal approaches for robotic prostatectomy.An exploration of men's experiences of undergoing active surveillance for favourable-risk prostate cancer: A mixed methods study protocol.Decision preparation, satisfaction and regret in a multi-center sample of men with newly diagnosed localized prostate cancer.A Longitudinal Study of Predictors of Sexual Dysfunction in Men on Active Surveillance for Prostate CancerHypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialCancer survivorship monitoring systems for the collection of patient-reported outcomes: a systematic narrative review of international approaches.Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of LifeUsing a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatmentCan erectile function be predicted after prostate cancer treatment?Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.Prediction of erectile function following treatment for prostate cancer.Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project.The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients.Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments.Potency preservation following stereotactic body radiation therapy for prostate cancer.Quality-of-life assessment tools for men with prostate cancer.Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.When study site contributes to outcomes in a multi-center randomized trial: a secondary analysis of decisional conflict in men with localized prostate cancer.
P2860
Q27311513-68734A6F-0D50-4A6D-822B-BE30653EB596Q30361302-62B018EA-D19E-46E1-8FDF-2BA8A26CAD1FQ30542816-672366E0-5B95-4A7B-A977-ABCE16B5CB0EQ30677640-98778889-03ED-4C91-9449-A1E352A5B6BBQ31156221-F55B705D-BB19-49AE-8D4F-1C85F518727AQ33691464-8980ADE6-3D76-439B-95C0-5D3A0B5587B4Q33919002-CF9CDD02-1D83-48BC-B9E9-13EB03D3BB4BQ34136485-44532E09-F14A-4820-8D08-DF2DCEA2DDBFQ34315605-DB1F8333-E4C1-426B-9B51-6C7BCDCCE90FQ34760295-25F15FB6-AE1C-4151-8EED-08AA5595F1ACQ35000485-553EA0EA-87FD-41A4-AAD6-A63C20465CF1Q35212795-C4378734-8491-4205-9CB8-05B84D0C1BB3Q35803168-39E7A64F-E4B1-4980-B175-84417F55FA21Q35949039-8E17937E-1D3C-4F21-83EB-F4E12A1D08C7Q36081535-0E6632B4-2012-487F-8C0D-7C9117F70AE2Q36092676-93DD42A4-D20F-45C4-9B44-FCADC9244D9BQ36131020-991F60B3-11FA-4900-9B92-659A8466DFF5Q36142085-CB8ED772-4AB4-44B9-84EF-09F68CAED869Q36333179-683071D4-EE22-444A-8D70-50D024CD6ADEQ36333403-A2D15CF7-2464-4D7B-9C9B-95464805B96AQ36575730-38961245-6E87-4EE1-930A-5E36398FEC4AQ36852329-FE2D4BAC-6E96-42D9-98A1-7214282EC0D0Q37035993-10B65CDD-DFAA-484F-94DC-40BF49131A8CQ37059743-048ED476-5F0C-42F0-8FEB-77DF98C6139EQ37074583-BFDAA5E1-DA9F-4227-9D37-0C48FD4214ECQ37222409-A28C1539-A9CF-4ABD-BF6F-F457E0F14EEFQ37253743-1C1A0228-D9CD-4D59-90F2-333CAE480405Q37253842-3F04F181-C8E6-43EF-9FE1-A56C4BEC4760Q37318611-55F2848A-FADB-4576-830E-61436CA3B9FCQ37356200-F89FF91D-9997-47C0-92F4-28BB8401DE43Q37385284-229722B2-CA37-4C00-9E2D-1AA137042BB1Q37523203-830B0EB6-8D1B-488B-B03D-A0883EE69A75Q38079169-619D670E-570B-40AF-9397-FE1BE58E8185Q38158080-AF1AB167-2066-4B05-ABFE-F46D8F7102D0Q38212832-EB1E0679-F9CB-4C44-8874-1DCBE8D72537Q38677828-4473CA55-BACC-4A26-B791-71F797290461Q38809389-B8BE5BE8-2D85-4FA1-9937-87C3B63D8C74Q38890085-959EEE5B-732C-4053-9388-1DB71EB17CC4Q39078034-2F05F3BD-83A4-4095-8357-E957018C2207Q39108288-14C618E8-F82A-4653-A79F-365288C99807
P2860
Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Development and validation of ...... ong prostate cancer survivors.
@en
Development and validation of ...... ong prostate cancer survivors.
@nl
type
label
Development and validation of ...... ong prostate cancer survivors.
@en
Development and validation of ...... ong prostate cancer survivors.
@nl
prefLabel
Development and validation of ...... ong prostate cancer survivors.
@en
Development and validation of ...... ong prostate cancer survivors.
@nl
P2093
P2860
P1433
P1476
Development and validation of ...... ong prostate cancer survivors.
@en
P2093
John T Wei
Konrad M Szymanski
Martin G Sanda
Rodney L Dunn
P2860
P304
P356
10.1016/J.UROLOGY.2010.01.027
P407
P577
2010-03-28T00:00:00Z